Corix Bioscience (OTCQB:CXBS) announced they will move the tissue cell culture and research divisions into a new Nevada facility.
As quoted in the press release:

This move will enable Corix to produce over 3 million plantlets in the immediate future and set them up to double that in the second full year. This new laboratory will be the first known tissue culture facility focused exclusively on the hemp and cannabis market. Until now, Corix relied on outside suppliers for seeds and clones. This will bring all propagation in-house. Part of the laboratory will be dedicated to the research of their proprietary CBD products and will require adding about 8 new employees.
Michael Ogburn, CEO of Corix Bioscience Inc., stated, “Moving into this new facility is going to give us the room we need to keep up with our aggressive expansion. We expect to produce over 750,000 plantlets just for ourselves next spring and sell the remaining 2.2 million plants on the wholesale market adding a potential $8 million in revenue. We also needed the space for the ongoing breeding of new strains for the medical industry’s ever-growing needs we’re seeing firsthand as the first major player for applications for cancer, the opioid epidemic, and other illnesses and diseases looking for treatments from the CBD oil.”


Click here to read the full press release.

Source: www.marketwired.com

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced the Company will have senior management participating in the following virtual financial community conferences and events during December 2020 .

  • Roth Deer Valley Consumer Conference – December 9 th to 11 th , 2020
  • Cantor Fitzgerald 2020 Virtual Cannabis MSO Summit – December 15 th to 16 th , 2020
  • MKM Partners – The Road Ahead, Preparation for 2021 Conference – December 15 th to 16 th , 2020

For more information regarding upcoming Curaleaf financial community conference and event participation please visit the investor relations section of the company website, under the events tab, at https://ir.curaleaf.com/events .

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less